Hamlet Protein announced the completion of new financing agreements with Nordea. The agreement significantly increases the company’s liquidity and provides flexibility to pursue further growth.

“Hamlet Protein has had a great relationship with Nordea over the years. The conclusion of the new financing agreements will see that relationship continues, as the facilities are more than adequate for our funding needs for the coming years,” commented Hamlet Protein CEO, Erik Visser.

Altor and Goldman Sachs acquired Hamlet Protein in 2015. CEO Erik Visser was appointed in June 2019 to further the company’s growth agenda. The improved financial position, coupled with strong shareholder support, makes Hamlet Protein a reliable and trustworthy partner for all its stakeholders.

“The financing agreements are tailored to the needs of Hamlet’s strategic plan and provide significantly increased liquidity. Furthermore, the new financing agreements resulted in reduced interest expenses, an extended maturity of the loan facilities, and added flexibility on the financial covenants,” concluded Erik Visser.